title: Response surface methodology to optimize novel fast disintegrating tablets using β cyclodextrin as diluent.
abstract: The objective of this work was to apply response surface approach to investigate main and interaction effects of formulation parameters in optimizing novel fast disintegrating tablet formulation using β cyclodextrin as a diluent. The variables studied were diluent (β cyclodextrin, X (1)), superdisintegrant (Croscarmellose sodium, X (2)), and direct compression aid (Spray dried lactose, X (3)). Tablets were prepared by direct compression method on B2 rotary tablet press using flat plain-face punches and characterized for weight variation, thickness, disintegration time (Y (1)), and hardness (Y (2)). Disintegration time was strongly affected by quadratic terms of β cyclodextrin, croscarmellose sodium, and spray-dried lactose. The positive value of regression coefficient for β cyclodextrin suggested that hardness increased with increased amount of β cyclodextrin. In general, disintegration of tablets has been reported to slow down with increase in hardness. However in the present study, higher concentration of β cyclodextrin was found to improve tablet hardness without increasing the disintegration time. Thus, β cyclodextrin is proposed as a suitable diluent to achieve fast disintegrating tablets with sufficient hardness. Good correlation between the predicted values and experimental data of the optimized formulation validated prognostic ability of response surface methodology in optimizing fast disintegrating tablets using β cyclodextrin as a diluent.
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Mercer University, Atlanta, Georgia 30341, USA. sameer.g.late@gsk.com
authors.forename: Sameer G
authors.initials: SG
authors.lastname: Late
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Banga
mesh_terms: D000932:Antiemetics / Q000737:chemistry*; D002266:Carboxymethylcellulose Sodium / Q000737:chemistry*; D004304:Dosage Forms; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005079:Excipients / Q000737:chemistry*; D017829:Granisetron / Q000737:chemistry*; D006244:Hardness; D007785:Lactose / Q000737:chemistry*; D015203:Reproducibility of Results; D012995:Solubility; D013607:Tablets; D047392:beta-Cyclodextrins / Q000737:chemistry*
chemical_list: D000932:Antiemetics; D002266:Carboxymethylcellulose Sodium; D004304:Dosage Forms; D005079:Excipients; D017829:Granisetron; D007785:Lactose; D013607:Tablets; D047392:beta-Cyclodextrins; C031215:betadex